Adeniran Adebowale J, Zhu Zhaowen, Gandhi Manoj, Steward David L, Fidler James P, Giordano Thomas J, Biddinger Paul W, Nikiforov Yuri E
Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45267-0529, USA.
Am J Surg Pathol. 2006 Feb;30(2):216-22. doi: 10.1097/01.pas.0000176432.73455.1b.
Papillary carcinoma is the most common type of thyroid malignancy. It has been recently shown that these tumors commonly have one of three genetic alterations: BRAF point mutations, RET/PTC rearrangements, or RAS point mutations. In this study, we analyze the relationship between these alterations and the microscopic features of papillary carcinomas, their clinical features, and prognostic characteristics. Ninety-seven papillary carcinomas were studied; in all cases, frozen tissue was available for nucleic acid extraction. Of 96 unselected cases, 42% were positive for BRAF, 18% for RET/PTC, and 15% for RAS mutations. Morphologic features were evaluated in detail in 61 cases and 6 characteristic nuclear features and 3 additional microscopic features were assessed quantitatively. At least 4 nuclear features were found in each tumor, with nuclear pseudoinclusions being the least frequent finding in all mutation groups. BRAF mutations were associated with older patient age, typical papillary appearance or the tall cell variant, a higher rate of extrathyroidal extension, and more advanced tumor stage at presentation. RET/PTC rearrangements presented at younger age and had predominantly typical papillary histology, frequent psammoma bodies, and a high rate of lymph node metastases. Tumors with RAS mutations were exclusively the follicular variant of papillary carcinoma and correlated with significantly less prominent nuclear features and low rate of lymph node metastases. These findings demonstrate that BRAF, RET/PTC, and RAS mutations are associated with distinct microscopic, clinical, and biologic features of thyroid papillary carcinomas.
乳头状癌是甲状腺恶性肿瘤最常见的类型。最近研究表明,这些肿瘤通常存在三种基因改变之一:BRAF点突变、RET/PTC重排或RAS点突变。在本研究中,我们分析了这些改变与乳头状癌的微观特征、临床特征及预后特征之间的关系。我们研究了97例乳头状癌;所有病例均有冷冻组织可用于核酸提取。在96例未经选择的病例中,42%的病例BRAF呈阳性,18%的病例RET/PTC呈阳性,15%的病例RAS呈突变阳性。对61例病例的形态学特征进行了详细评估,并对6种特征性核特征和3种其他微观特征进行了定量评估。每个肿瘤至少发现4种核特征,核假包涵体在所有突变组中出现频率最低。BRAF突变与患者年龄较大、典型乳头状外观或高细胞变体、甲状腺外侵犯率较高以及就诊时肿瘤分期较晚相关。RET/PTC重排多见于较年轻患者,主要为典型乳头状组织学,砂粒体常见,淋巴结转移率高。具有RAS突变的肿瘤均为乳头状癌的滤泡变体,与核特征不明显及淋巴结转移率低显著相关。这些发现表明,BRAF、RET/PTC和RAS突变与甲状腺乳头状癌不同的微观、临床和生物学特征相关。